Posters

Efficacy of intravitreal injection of dexamethasone implant (Ozurdex) in patient with macular edema after retinal vein occlusion

Poster Details

First Author: O. Tumanova RUSSIAN FEDERATION

Co Author(s):    I. Medvedev   N. Dergacheva                 

Abstract Details

Purpose:

To study morphological and functional characteristics of an eye in patients with macular edema developed after a central vein (CRVO) and/or vein branch (BRVO) occlusion after intravitreal dexamethasone implant (Ozurdex) injection.

Setting:

Medvedev I.,MD, Tumanova O. MD, Dergacheva N, International Eye Care Center, Moscow, Russia

Methods:

There were 9 patients (9 eyes) in to the analysis. The mean age was 65,8 years. Dexamethasone implant (Ozurdex) was applied by standard method on an ambulatory basis. The average period before the implantation lasted 1  month; an average follow-up -3,0 month.

Results:

Efficiency of treatment was evaluated according to the dynamics of retinal thickness by optical coherence tomography and best-corrected visual acuity. The average retinal thickness before implantation- 464microns, after 1 month - 309microns, 2 month- 330microns, 3 month-403microns, 6 month-460microns. Visual acuity before implantation- 20/63, after 1 month-20/140, 2 month-20/140; 3 month-20/100. IOP- before implantation-15,4 mm.m.c, after 1month-19,7; 2 month-19,3; 3 month-17,5.

Conclusions:

Dexamethasone implant is an effective method of treatment of macular edema developed as a result of the CRVO/BRVO, but stable effect persists for 2-3 months.

Financial Disclosure:

NONE